The platelet integrin receptor α IIb β 3 (GPIIb/IIIa) plays a critical role in thrombosis and hemostasis by mediating interactions between platelets and several ligands, primarily fibrinogen.

In the setting of percutaneous coronary revascularization, agents in the class known as platelet glycoprotein IIb/IIIa inhibitors have significantly reduced the incidence of death or nonfatal ...

The study, which appears in the Jan. 17 edition of the Journal of Cell Biology, indicates that CIB1 binds to and keeps the platelet adhesion receptor GPIIb/IIIa in an inactive state, thus blocking ...

The αIIbβ3 integrin, also known as the platelet fibrinogen receptor or GP IIb-IIIa, has been the focus of an entire class of blood-thinning drugs, called GPIIb-IIIa agonists. The Penn ...

C. Michael Gibson and Dean Kereiakes discuss the first human use of RUC-4, designed for STEMI point-of-care treatment. Receive the the latest news, research, and presentations from major meetings ...

By targeting platelet GPIIb/IIIa receptors, the final common pathway in platelet aggregation, RUC-4 inhibits platelet aggregation caused by all platelet activators and can, under some conditions ...

This contrasts with the overall finding. Testing for platelet stickiness and a patient’s GPIIb/IIIa status could determine which people need anticlotting drugs beyond aspirin–and for how long ...

The research group found that in addition to CLEC-2, a second platelet receptor, GPIIb/IIIa, is involved in the development of cerebral venous thrombosis and that only the interaction of both ...

SAN DIEGO---CeleCor Therapeutics, Inc. today announced preliminary positive results in the company’s ongoing phase 1 clinical study with RUC-4, a novel subcutaneous platelet GPIIb/IIIa inhibitor, ...

The study, which appears in the Jan. 17 edition of the Journal of Cell Biology, indicates that CIB1 binds to and keeps the platelet adhesion receptor GPIIb/IIIa in an inactive state, thus blocking ...